Conveglipron

Conveglipron
Clinical data
Other names	HDM-1002; HDM1002
Routes of; administration	Oral
Drug class	GLP-1 receptor agonist; Antidiabetic agent; Antiobesity agent
Identifiers
	IUPAC name 2-[[4-[6-[[2-fluoro-4-(oxetan-3-yl)phenyl]methoxy]-2-pyridinyl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid;
CAS Number	2886728-09-0;
PubChem CID	166540968;
ChemSpider	129787062;
ChEMBL	ChEMBL5590455;
Chemical and physical data
Formula	C33H35FN4O5
Molar mass	586.664 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C7COC7)F;
	InChI InChI=1S/C33H35FN4O5/c34-27-14-22(25-18-41-19-25)4-5-24(27)20-43-32-3-1-2-28(36-32)21-8-11-37(12-9-21)17-31-35-29-7-6-23(33(39)40)15-30(29)38(31)16-26-10-13-42-26/h1-7,14-15,21,25-26H,8-13,16-20H2,(H,39,40)/t26-/m0/s1; Key:SFKAXUUDIGSMBK-SANMLTNESA-N;

Conveglipron (INNTooltip International Nonproprietary Name; developmental code name HDM1002) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus.^[1]^[3]^[2]^[4]^[5] It is taken orally.^[1]^[2] The drug is a small molecule and is a selective and highly potent full agonist of the GLP-1 receptor with antihyperglycemic and antiobesity effects in animals.^[5] Conveglipron is under development by Huadong Medicine in China.^[1]^[3]^[2] As of January 2026, it is in phase 3 clinical trials for type 2 diabetes, phase 2 trials for obesity, and phase 1 trials for diabetes mellitus.^[1]^[3]^[2]

References

^ ^a ^b ^c ^d ^e "HDM 1002". AdisInsight. Springer Nature Switzerland AG. 14 January 2026. Retrieved 18 February 2026.
^ ^a ^b ^c ^d ^e "Conveglipron". OZMOSI.
^ ^a ^b ^c "Delving into the Latest Updates on Conveglipron with Synapse". Synapse. 11 February 2026. Retrieved 18 February 2026.
^ Pu J, Huang Y, Wan L, Zhu M, Wei H, Gao H, et al. (October 2025). "First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers". Diabetes, Obesity & Metabolism. 27 (10): 5622–5631. doi:10.1111/dom.16610. PMID 40662378.
^ ^a ^b Pan H, Zhai W, Zhang Z, Guo L, Dong Z, Zhao M, et al. (2023). "59th EASD Annual Meeting of the European Association for the Study of Diabetes: Hamburg, Germany, 2 - 6 October 2023: Discovery of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist for treatment of type 2 diabetes and obesity". Diabetologia. 66 (Suppl 1): S1–S536 (S316). doi:10.1007/s00125-023-05969-6. hdl:10553/132806. ISSN 0012-186X. Retrieved 18 February 2026.